Robert Dee Etherington - 29 Jun 2023 Form 4 Insider Report for Clene Inc. (CLNN)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CLNN
Reported as of: 29 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2023, 13:49:59 UTC
Prior SEC filing: 27 Jun 2023
Next SEC filing: 10 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jerry Miraglia POA

Key filing fact

Robert Dee Etherington filed Form 4 for Clene Inc. (CLNN) on 03 Jul 2023.

Key facts

This page summarizes Robert Dee Etherington's Form 4 filing for Clene Inc. (CLNN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jul 2023, 13:49.

Change

Previous filing in this sequence was filed on 27 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLNN transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +900,000
Change %
Price: $0.000000
Shares after: 900,000
Date: 29 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 900,000
Exercise price: $0.9000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on June 29, 2023 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.90 per share. The options vest with respect to the first 25% of such shares on June 29, 2024 and then in 36 equal installments of the balance of the shares of Common Stock on the last day of each calendar month beginning July 29, 2024 until such shares are fully vested. If Clene Inc. has an NDA accepted by the FDA, 50% of the option shares shall vest on that date. If the FDA approves the accepted NDA, the then remaining unvested option shares shall vest on that date.